<DOC>
	<DOCNO>NCT00801944</DOCNO>
	<brief_summary>Prospective , double-blind , double-randomised , 2-arm parallel group study . Optimal dose increase . Primary efficacy assessment OAB symptoms patient diary .</brief_summary>
	<brief_title>Solifenacin Succinate 5mg 10mg Once Daily Treatment Urgency Symptoms</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Solifenacin Succinate</mesh_term>
	<criteria>Patient willing able complete micturition diary correctly . Symptoms overactive bladder ( include urinary frequency , urgency with/without urge incontinence ) &gt; = 3 month At least 3 episode urgency without incontinence last 3 day At least three episode urgency without incontinence ( PPIUS grade 3 4 ) 3day micturition diary period Patient must experience frequency micturition average &gt; = 8 time per 24hour period 3day micturition diary period Pregnant woman woman intend become pregnant study woman childbearing potential sexually active practise unreliable method birth control lactate study . Reliable contraceptive method intrauterine device , contraceptive pill combination type , hormonal implant injectable patch contraceptive Clinically significant outflow obstruction ( discretion investigator ) Significant post void residual volume ( PVR &gt; 200ml ) Significant stress incontinence mixed stress/urge incontinence stress predominant factor determine investigator Patient indwell catheter practise intermittent selfcatheterisation Evidence symptomatic urinary tract infection , chronic inflammation interstitial cystitis , bladder stone , previous pelvic radiation therapy previous current malignant disease pelvic organ Hypersensitivity solifenacin excipients , uncontrolled narrow angle glaucoma , myasthenia gravis , urinary gastric retention , severe renal impairment ( GFR â‰¥30 ml/min ) , moderate severe hepatic impairment , chronic intestinal disease , megacolon , requirement dialysis , concomitant use strong CYP3A4 inhibitor , e.g . ketoconazole Non drug OAB treatment bladdertraining , biofeedback pelvic floor exercise permissible establish least 4 week prior study start intend continue throughout study ; electrostimulation therapy permissible time Use drug intend treat urinary incontinence Diabetic neuropathy Any clinically significant condition , opinion investigator make patient unsuitable trial Participation clinical trial within 30 day prior randomisation Employees Yamanouchi Group , third party associate study , study site Patient complete micturition diary accord instruction</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Overactive Bladder</keyword>
</DOC>